Comment on CMS-2026-1256-0002
Johnson & JohnsonOtherBusiness
Summary: Johnson & Johnson submitted comments regarding the FY 2027 IPPS proposed rule, expressing strong opposition to the repeal of alternative pathways for New Technology Add-on Payments (NTAP) and Transitional Pass-Through (TPT) payments for breakthrough devices. While they oppose specific payment repeals, they also offer a mix of support, recommendations for refinements, and requests for further information regarding various MS-DRG restructurings and delivery reform models like CJR-X and TEAM.
Johnson & Johnson (“J&J”) is pleased to submit the following comments and recommendations in response to the proposed rule [CMS-1833-P] released by the Centers for Medicare & Medicaid Services (CMS, or the Agency) on April 10, 2026. Please see attached our detailed comments.